Noninvasive imaging and radiovirotherapy of prostate cancer using an oncolytic measles virus expressing the sodium iodide symporter

Pavlos Msaouel, Ianko D. Iankov, Cory Allen, Ileana Aderca, Mark J Federspiel, Donald J. Tindall, John C. Morris, Michael Koutsilieris, Stephen J Russell, Evanthia Galanis

Research output: Contribution to journalArticle

59 Citations (Scopus)

Abstract

Prostate cancer cells overexpress the measles virus (MV) receptor CD46. Herein, we evaluated the antitumor activity of an oncolytic derivative of the MV Edmonston (MV-Edm) vaccine strain engineered to express the human sodium iodide symporter (NIS; MV-NIS virus). MV-NIS showed significant cytopathic effect (CPE) against prostate cancer cell lines in vitro. Infected cells effectively concentrated radioiodide isotopes as measured in vitro by Iodide-125 ( 125I) uptake assays. Virus localization and spread in vivo could be effectively followed by imaging of 123 I uptake. In vivo administration of MV-NIS either locally or systemically (total dose of 9 × 106 TCID50) resulted in significant tumor regression (P<0.05) and prolongation of survival (P<0.01). Administration of 131 I further enhanced the antitumor effect of MV-NIS virotherapy (P 0.05). In conclusion, MV-NIS is an oncolytic vector with significant antitumor activity against prostate cancer, which can be further enhanced by 131 I administration. The NIS transgene allows viral localization and monitoring by noninvasive imaging which can facilitate dose optimization in a clinical setting.

Original languageEnglish (US)
Pages (from-to)2041-2048
Number of pages8
JournalMolecular Therapy
Volume17
Issue number12
DOIs
StatePublished - Dec 2009

Fingerprint

Oncolytic Viruses
Measles virus
Prostatic Neoplasms
Viruses
Virus Receptors
Iodides
sodium-iodide symporter
Transgenes
Isotopes
Vaccines
Cell Line
Survival

ASJC Scopus subject areas

  • Molecular Biology
  • Molecular Medicine
  • Genetics
  • Drug Discovery
  • Pharmacology

Cite this

Noninvasive imaging and radiovirotherapy of prostate cancer using an oncolytic measles virus expressing the sodium iodide symporter. / Msaouel, Pavlos; Iankov, Ianko D.; Allen, Cory; Aderca, Ileana; Federspiel, Mark J; Tindall, Donald J.; Morris, John C.; Koutsilieris, Michael; Russell, Stephen J; Galanis, Evanthia.

In: Molecular Therapy, Vol. 17, No. 12, 12.2009, p. 2041-2048.

Research output: Contribution to journalArticle

Msaouel, Pavlos ; Iankov, Ianko D. ; Allen, Cory ; Aderca, Ileana ; Federspiel, Mark J ; Tindall, Donald J. ; Morris, John C. ; Koutsilieris, Michael ; Russell, Stephen J ; Galanis, Evanthia. / Noninvasive imaging and radiovirotherapy of prostate cancer using an oncolytic measles virus expressing the sodium iodide symporter. In: Molecular Therapy. 2009 ; Vol. 17, No. 12. pp. 2041-2048.
@article{aa0e14927a144485927421d5db4a7c6a,
title = "Noninvasive imaging and radiovirotherapy of prostate cancer using an oncolytic measles virus expressing the sodium iodide symporter",
abstract = "Prostate cancer cells overexpress the measles virus (MV) receptor CD46. Herein, we evaluated the antitumor activity of an oncolytic derivative of the MV Edmonston (MV-Edm) vaccine strain engineered to express the human sodium iodide symporter (NIS; MV-NIS virus). MV-NIS showed significant cytopathic effect (CPE) against prostate cancer cell lines in vitro. Infected cells effectively concentrated radioiodide isotopes as measured in vitro by Iodide-125 ( 125I) uptake assays. Virus localization and spread in vivo could be effectively followed by imaging of 123 I uptake. In vivo administration of MV-NIS either locally or systemically (total dose of 9 × 106 TCID50) resulted in significant tumor regression (P<0.05) and prolongation of survival (P<0.01). Administration of 131 I further enhanced the antitumor effect of MV-NIS virotherapy (P 0.05). In conclusion, MV-NIS is an oncolytic vector with significant antitumor activity against prostate cancer, which can be further enhanced by 131 I administration. The NIS transgene allows viral localization and monitoring by noninvasive imaging which can facilitate dose optimization in a clinical setting.",
author = "Pavlos Msaouel and Iankov, {Ianko D.} and Cory Allen and Ileana Aderca and Federspiel, {Mark J} and Tindall, {Donald J.} and Morris, {John C.} and Michael Koutsilieris and Russell, {Stephen J} and Evanthia Galanis",
year = "2009",
month = "12",
doi = "10.1038/mt.2009.218",
language = "English (US)",
volume = "17",
pages = "2041--2048",
journal = "Molecular Therapy",
issn = "1525-0016",
publisher = "Nature Publishing Group",
number = "12",

}

TY - JOUR

T1 - Noninvasive imaging and radiovirotherapy of prostate cancer using an oncolytic measles virus expressing the sodium iodide symporter

AU - Msaouel, Pavlos

AU - Iankov, Ianko D.

AU - Allen, Cory

AU - Aderca, Ileana

AU - Federspiel, Mark J

AU - Tindall, Donald J.

AU - Morris, John C.

AU - Koutsilieris, Michael

AU - Russell, Stephen J

AU - Galanis, Evanthia

PY - 2009/12

Y1 - 2009/12

N2 - Prostate cancer cells overexpress the measles virus (MV) receptor CD46. Herein, we evaluated the antitumor activity of an oncolytic derivative of the MV Edmonston (MV-Edm) vaccine strain engineered to express the human sodium iodide symporter (NIS; MV-NIS virus). MV-NIS showed significant cytopathic effect (CPE) against prostate cancer cell lines in vitro. Infected cells effectively concentrated radioiodide isotopes as measured in vitro by Iodide-125 ( 125I) uptake assays. Virus localization and spread in vivo could be effectively followed by imaging of 123 I uptake. In vivo administration of MV-NIS either locally or systemically (total dose of 9 × 106 TCID50) resulted in significant tumor regression (P<0.05) and prolongation of survival (P<0.01). Administration of 131 I further enhanced the antitumor effect of MV-NIS virotherapy (P 0.05). In conclusion, MV-NIS is an oncolytic vector with significant antitumor activity against prostate cancer, which can be further enhanced by 131 I administration. The NIS transgene allows viral localization and monitoring by noninvasive imaging which can facilitate dose optimization in a clinical setting.

AB - Prostate cancer cells overexpress the measles virus (MV) receptor CD46. Herein, we evaluated the antitumor activity of an oncolytic derivative of the MV Edmonston (MV-Edm) vaccine strain engineered to express the human sodium iodide symporter (NIS; MV-NIS virus). MV-NIS showed significant cytopathic effect (CPE) against prostate cancer cell lines in vitro. Infected cells effectively concentrated radioiodide isotopes as measured in vitro by Iodide-125 ( 125I) uptake assays. Virus localization and spread in vivo could be effectively followed by imaging of 123 I uptake. In vivo administration of MV-NIS either locally or systemically (total dose of 9 × 106 TCID50) resulted in significant tumor regression (P<0.05) and prolongation of survival (P<0.01). Administration of 131 I further enhanced the antitumor effect of MV-NIS virotherapy (P 0.05). In conclusion, MV-NIS is an oncolytic vector with significant antitumor activity against prostate cancer, which can be further enhanced by 131 I administration. The NIS transgene allows viral localization and monitoring by noninvasive imaging which can facilitate dose optimization in a clinical setting.

UR - http://www.scopus.com/inward/record.url?scp=73849122720&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=73849122720&partnerID=8YFLogxK

U2 - 10.1038/mt.2009.218

DO - 10.1038/mt.2009.218

M3 - Article

C2 - 19773744

AN - SCOPUS:73849122720

VL - 17

SP - 2041

EP - 2048

JO - Molecular Therapy

JF - Molecular Therapy

SN - 1525-0016

IS - 12

ER -